$6.61
-0.01 (-0.15%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DMAC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 4 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Squarepoint Ops LLC, AQR CAPITAL MANAGEMENT LLC) · FINRA short interest 27.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)NCT05065216Stroke RecoveryRandomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Drug: Recombinant human tissue kallikrein · Other: Placebo for DM199 Solution for Injection | Acute Stroke, Ischemic Stroke, Stroke | 728 | Dec 2026 | ≤ 134 d | 2026-04-28 |
| DM199 for Pregnancy ComplicationsNCT06875141Incidence of treatment adverse eventsOpen-label · Other | Not applicable | Withdrawnsponsor's stated reason: This entry was unauthorized and has been withdrawn. | Biological: DM199 | Pre-Eclampsia | 0 | May 2025 | — | 2025-06-04 |
| Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)NCT04123613Incidence of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: DM199 | Kidney Diseases | 79 | 2022-03-16actual | — | 2022-03-31 |
| Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic StrokeNCT03290560Number of participants with treatment-related adverse events as assessed by CTCAE v4.3Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Recombinant human tissue kallikrein · Other: Placebo | Acute Ischemic Stroke | 92 | 2020-01-23actual | — | 2022-03-31 |
| Study to Assess PK, Safety and Tolerability in Patients With DM and CKDNCT03795389Safety as assessed by incidence, severity, and causality of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: DM199 | Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes | 33 | 2019-07-21actual | — | 2021-09-13 |
| An Open Label, Phase 1b, Ascending Dose Study of DM199NCT02868996Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Recombinant human tissue kallikrein | Stroke | 36 | Mar 2017actual | — | 2017-12-07 |
| A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes PatientsNCT01845064Safety and tolerability of single and multiple subcutaneous doses of DM199Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: DM199, Placebo | Diabetes Type 2 | 98 | Sep 2014actual | — | 2014-12-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19